These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35349744)

  • 1. Recombinant subunits of SARS-CoV-2 spike protein as vaccine candidates to elicit neutralizing antibodies.
    Noorabad Ghahroodi F; Khalili S; Rasaee MJ
    J Clin Lab Anal; 2022 May; 36(5):e24328. PubMed ID: 35349744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.
    Ravichandran S; Coyle EM; Klenow L; Tang J; Grubbs G; Liu S; Wang T; Golding H; Khurana S
    Sci Transl Med; 2020 Jul; 12(550):. PubMed ID: 32513867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models.
    Nazarian S; Olad G; Abdolhamidi R; Motamedi MJ; Kazemi R; Kordbacheh E; Felagari A; Olad H; Ahmadi A; Bahiraee A; Farahani P; Haghighi L; Hassani F; Hajhassan V; Nadi M; Sheikhi A; Salimian J; Amani J
    Mol Immunol; 2022 Sep; 149():107-118. PubMed ID: 35802999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
    Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
    Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
    Jangra S; Landers JJ; Rathnasinghe R; O'Konek JJ; Janczak KW; Cascalho M; Kennedy AA; Tai AW; Baker JR; Schotsaert M; Wong PT
    Front Immunol; 2021; 12():729189. PubMed ID: 34603303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of Neutralizing Antibody of PastoCoAd Vaccine Candidates against a Variant of Concern of SARS-CoV-2 in Animal Models.
    Panahi M; Teimoori A; Esmaeili S; Aminianfar H; Milani A; Hosseini SY; Esmaeili P; Biglari A; Baesi K
    Iran Biomed J; 2024 Jul; 28(4):214-20. PubMed ID: 39044638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
    Su QD; Zou YN; Yi Y; Shen LP; Ye XZ; Zhang Y; Wang H; Ke H; Song JD; Hu KP; Cheng BL; Qiu F; Yu PC; Zhou WT; Zhao R; Cao L; Dong GF; Bi SL; Wu GZ; Gao GF; Zheng J
    Vaccine; 2021 Feb; 39(8):1241-1247. PubMed ID: 33516600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
    Fougeroux C; Goksøyr L; Idorn M; Soroka V; Myeni SK; Dagil R; Janitzek CM; Søgaard M; Aves KL; Horsted EW; Erdoğan SM; Gustavsson T; Dorosz J; Clemmensen S; Fredsgaard L; Thrane S; Vidal-Calvo EE; Khalifé P; Hulen TM; Choudhary S; Theisen M; Singh SK; Garcia-Senosiain A; Van Oosten L; Pijlman G; Hierzberger B; Domeyer T; Nalewajek BW; Strøbæk A; Skrzypczak M; Andersson LF; Buus S; Buus AS; Christensen JP; Dalebout TJ; Iversen K; Harritshøj LH; Mordmüller B; Ullum H; Reinert LS; de Jongh WA; Kikkert M; Paludan SR; Theander TG; Nielsen MA; Salanti A; Sander AF
    Nat Commun; 2021 Jan; 12(1):324. PubMed ID: 33436573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
    Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
    Wang Y; Wang L; Cao H; Liu C
    J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.